Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocks

The Indian pharma sector is heavily reliant on the US market, and any policy changes like tariffs directly impact profitability, especially for companies focusing on patented or specialty drugs. This news highlights a potential shift in US trade policy under a new administration.

Focus on Indian pharma companies with strong generic pipelines or those less exposed to patented drugs in the US, while being cautious on specialty pharma players.

For Indian markets, this story mainly matters for SUNPHARMA, and the Pharmaceuticals pocket. The current signal is bearish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Faces the steepest risk due to exposure to patented drugs targeted by US tariffs. As a CDMO, may see selective impact from the tariffs. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •US has imposed up to 100% tariffs on patented drugs.
• •Generics and biosimilars are spared from these tariffs.
• •Indian specialty pharma players are exposed to this risk.
• •Sun Pharma faces the steepest risk among Indian pharma companies.
• •CDMOs like Sai Lifesciences may experience selective impact.